Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders. Asset acquisition is projected to add approximately $6 million to $8 million of revenue in 2026 in a key gastroenterology market that leverages Merit’s existing commercial footprint. SOUTH JORDAN, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announ ...

Accessibility StatementSkip Navigation The C2 CryoBalloonâ"¢ has been part of PENTAX Medical's therapeutic portfolio since 2017, offering a minimally invasive option to treat patients suffering from Barrett's Esophagus and other gastrointestinal disorders. The minimally invasive device delivers controlled cryotherapy to ablate unwanted tissue while preserving surrounding structures. Under Merit Medical's stewardship, the technology is expected to reach new levels of adoption and impact, expanding access to ...

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. Parties interested in participating by phone should regi ...

Core Insights - Abbott Laboratories reported earnings per share (EPS) of $1.30, matching estimates, with revenue at approximately $11.37 billion, slightly below the expected $11.39 billion [1][6] Financial Performance - The company's third-quarter sales increased by 6.9%, reaching $11.37 billion, driven by strong performance in medical devices and diagnostics, despite a normalization in COVID-19 testing-related revenue [2][6] - Organic sales rose by 5.5%, or 7.5% when excluding COVID-19 testing-related revenue [2] - Abbott's operating margin was reported at 18.1% of sales, with an adjusted operating margin of 23%, marking a 40 basis point increase [3] Earnings Metrics - The GAAP diluted EPS for the quarter stood at $0.94, while the adjusted diluted EPS was $1.30, an increase from $1.21 per share reported in the same quarter last year [3][6] Management Commentary - CEO Robert Ford emphasized the company's consistent, high-quality performance, attributing it to their differentiated product pipeline [4] - Abbott has reaffirmed its full-year guidance, indicating confidence in its ongoing business strategy and market position [4] Valuation and Financial Ratios - The company's price-to-earnings (P/E) ratio is approximately 16.07, reflecting the market's valuation of its earnings [4] - Abbott's financial metrics include a debt-to-equity ratio of approximately 0.27 and a current ratio of around 1.82, suggesting a strong financial position [5] - The enterprise value to sales ratio is around 5.36, providing insight into its valuation relative to its sales [5] - Abbott's earnings yield is about 6.22%, offering a perspective on its earnings relative to its share price [5]

Core Insights - Abbott Laboratories reported third-quarter results that were largely in line with expectations, with earnings matching forecasts but revenue slightly below consensus [1] Financial Performance - The company posted earnings per share of $1.30, meeting analyst projections [2] - Revenue came in at $11.37 billion, just under expectations of $11.4 billion [2] - Reported sales increased 6.9% year-over-year, or 5.5% organically, and grew 7.5% when excluding COVID-19 testing-related revenue [2] Future Guidance - For the full year 2025, Abbott guided for earnings of $5.12 to $5.18 per share, compared with Wall Street's consensus of $5.14 [3] - The company maintained its outlook for organic sales growth of 7.5% to 8.0%, excluding COVID-related sales impacts, and 6.0% to 7.0% when including them [3] - Executives noted solid underlying demand across medical devices and nutrition products, though diagnostics sales continued to normalize following the pandemic [3]

Welcome to Market Catalyst. I'm Julie Hyman. We are 30 minutes into the US trading day.Here's what we're watching this hour. First up, big bank earnings kicking off a strong start for reporting season. We've got full coverage coming up.Plus, we'll have the latest on trade tensions between the US and China. And what do ETF lows tell us about the state of the markets. We'll discuss that and much more on Market Catalyst.Let's start with the major averages. Take a look at what's happening in markets today. We'r ...

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Wednesday's key moments. 1. The stock market is higher Wednesday as a rollout of better-than-expected earnings overshadowed investor concerns on intensifying U.S.- China trade talks. President Donald Trump 's latest threat to China on Tuesday afternoon derailed the S & P 500's rally attempt. That failed comeback had been fueled by earlier comments from Fed Chair Jerome Powell sugges ...

Key Takeaways Abbott posted Q3 adjusted EPS of $1.30, matching estimates and rising 7.4% year over year.ABT's Q3 sales grew 6.9% to $11.37B, led by strong growth in the Medical Devices and Nutrition units.Abbott's full-year EPS guidance was reaffirmed at $5.12$5.18, with organic sales growth of 7.5%8%.Abbott Laboratories (ABT) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.30, which came in line with the Zacks Consensus Estimate. The figure improved 7.4% from the prior-year quarter’s le ...

This Couple Made Millions On Amazon Selling Banned ‘Dechoker’ Medical Devices, FDA Says https://t.co/xxD5H6A3mu ...

By Christy Santhosh and Kamal Choudhury (Reuters) -Abbott missed analysts' third-quarter revenue estimates on Wednesday, as weakness in its diagnostics and nutrition businesses outweighed robust demand for its medical devices. The company had flagged volatility in the businesses as it navigates a sharp decline in COVID-19 testing demand, new U.S. tariffs, and a freeze on foreign aid by President Donald Trump's administration. The diagnostics division is also facing pricing pressure from China's procurem ...